BEVERLY-2 trial (NCT00717405)[4] is a phase 2 study designed to determine the efficacy and safety of the combination of bevacizumab with neoadjuvant and adjuvant chemotherapy and trastuzumab in patients with non-metastatic inflammatory breast cancer with HER2 overexpression. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.